Department of Radiation Oncology

Robert Prosnitz, M.D., M.P.H.

Work Contact Information:

Hospital of the University of Pennsylvania 3400 Spruce Street 2nd Floor Donner Building Department of Radiation Oncology Philadelphia, PA 19104

Education:
M.P.H., Harvard University School of Public Health, Boston, MA		2000
	Track:  Clinical Effectiveness
Program in Clinical Effectiveness, Harvard Medical School and Harvard School of Public Health, Boston, MA		1999
M.D., Duke University School of Medicine, Durham, NC		1996
B.A., Yale University, New Haven, CT		1991
	Major:  Economics and Political Science, Cum Laude
Post Doctoral Training:
Harvard Joint Center for Radiation Therapy, Boston, MA		2000-2001
	Chief Resident
Harvard Joint Center for Radiation Therapy, Boston, MA		1997-2000
	Resident
Beth Israel Hospital, Boston, MA		1996-1997
	Intern, Dept. of Medicine
Medical Licensure:
	Connecticut, 2007-present
	North Carolina, 2001-present
	Virginia, 2001-2005
Board Certification:
	Radiation Oncology (American Board of Radiology)	June 11, 2001
Employment History:
Hospital of the University of Pennsylvania, Dept. of Radiation Oncology
	Assistant Professor	2009-present
Radiation Oncology Specialists of Southern Connecticut
	Associate	2007-2008
Duke University Medical Center, Dept. of Radiation Oncology
	Assistant Professor	2006-2007
	Associate	2001-2005
Professional Societies:
	American Society for Therapeutic Radiology and Oncology, Member, 2001-present
	Member, Health Services Research Committee, 2005-2007
	American College of Radiology, Member, 2001-present.
	American Society of Clinical Oncology, Member, 2001-present
	North Carolina Medical Society, Member, 2001-2007
	Durham-Orange County Medical Society, Member, 2001-2007
	Society for Medical Decision Making, Member, 2008-present

 Research Experience:

• “A Phase II Study of Rituximab Followed by Involved-Field Radiation in Patients with Lymphocyte Predominance Hodgkin’s Disease.” DUMC IRB# 5371-03-11R0.  Principal Investigator, 2004-2007.
• RTOG 0413/NSABP Protocol B-39, “A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer.”  DUMC IRB # 7316-05-6.  Site Principal-Investigator, 2006-2007.
• Protocol SCSSc-01.  “A Randomized, Open-Label, Phase II/III Multi-Center Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide and ATGAM, and  Autologous Transplantation with Auto-CD34+HPC versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis.”  DUMC IRB # 6560.  Site Co-Investigator and Total Body Irradiation Consultant for Trial, 2005-2007.
• “Pathophysiologic Impact of Doxorubicin and Radiation Therapy on the Heart of Patients Treated for Breast Cancer.”  DUMC IRB# 0433-02-2R4.  DAMD  17-98-1-8071 and BC010663.  Co-Investigator, 2001-2006.
• Protocol RSR13 RT-016, “A Phase 3 Randomized, Open-Label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with our Without Concurrent RSR13 (efaproxiral), in Women with Brain Metastases from Breast Cancer.”  DUMC IRB# 6291-04-9.  Site Co-Investigator, 2005-2006.
• RTOG 9804, “Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In-Situ (DCIS) of the Female Breast.”  DUMC IRB# 7012-05-3.  Site Principal Investigator, 2001-2005.

Didactic Lectures:

• Annual Lecture to Duke Radiation Oncology Residents on “Post-Mastectomy Radiation Therapy”, 2002-2007.
• Lecture to Duke Medical Oncology Fellows on “Role of Radiation Therapy in the Treatment of Breast Cancer”, June 2002.
• Annual Lecture to Duke Radiation Oncology Residents on “Early-Stage Hodgkin’s Disease”, 2002-2007.
• Lecture to Hospital of Saint Raphael Surgery Residents on “Radiation Therapy in the Management of Breast Cancer Patients”, 2008-present.

Publications in Refereed Journals:

• Prosnitz RG, Schneider L, Manola J, Rocha S, Loffredo M, Lopes L, D’Amico AV.   “Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer:  results of a pilot study.”  Int J Radiat Oncol Biol Phys 1999;45:563-566.
• Ibom VK, Prosnitz RG, Gong JZ, Moore JO, DeCastro CM, Prosnitz LR, Rizzieri DA, Gockerman JP.  “Rituximab in lymphocyte predominance Hodgkin's disease: a case series.”  Clin Lymphoma 2003;4:115-118.
• Miller KL, Marks LB, Barrier RC, Jr, Leight GS, Clough RW, Prosnitz RG, Bentley RC. “Increased sectioning of pathologic specimens with ductal carcinoma in situ of the breast: are there clinical consequences?”  Clin Breast Cancer 2003;4:198-202.
• Yu X, Prosnitz RG, Zhou S, Hardenbergh PH, Tisch A, Blazing MA, Borges-Neto S, Hollis D, Wong T, Marks LB.  “Symptomatic “Cardiac” Events Following Radiation Therapy (RT) for Left-sided Breast Cancer:  Possible Association with RT-Induced Changes in Regional Perfusion.”  Clinical Breast Cancer 2003; 4: 193-197.
• Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM.  “Pretreatment Hemoglobin Levels Are Correlated with the Effectiveness of Radiation and Concurrent Chemotherapy in Advanced Head and Neck Cancer”.  Int J Radiat Oncol Biol Phys 2005; 61:1087-95.
• Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RG, Downey MA, Scher RL.  “Necessity for Adjuvant Neck Dissection in Setting of Concurrent Chemoradiation for Head and Neck Cancer.  Int J Radiat Oncol Biol Phys 2004; 58:1418-1423.
• Prosnitz RG, Chen YH, Marks LB.  “Cardiac Toxicity Following Thoracic Radiation.”  Semin Oncol 2005; 32:S71-870.
• Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S.  “The incidence and functional consequences of RT-associated cardiac perfusion defects.” Int J Radiat Oncol Biol Phys 2005; 63:214-223.
• Goldberg G, Prosnitz RG, Olson JA, Marks LB.  “Definition of postlumpectomy tumor bed for radiotherapy boost field planning: CT versus surgical clips.  Int J Radiat Oncol Biol Phys Int 2005; 63:209-213.
• Allen AM, Prosnitz RG, Ten Haken RK, Normolle DP, Yu X, Zhou S, Marsh R, Marks LB, Pierce LJ. “Body Mass Index Predicts the Incidence of Radiation Pneumonitis in Breast Cancer Patients.” The Cancer Journal 2005; 11:390-398.
• Raj KA, Marks LM, and Prosnitz RG. “Late Effects of Breast Radiotherapy in Young Women”.  Breast Disease 2005-2006; 23:55-65.
• Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, and Prosnitz LR. Combined Modality Therapy versus Radiotherapy Alone for Treatment of Early Stage Hodgkin’s Disease: Cure versus Complications.”  J Clin Oncol 2006; 24:605-611.
• Raj KA, Evans ES, Prosnitz RG, Quaranta BP, Hardenbergh PH, Hollis DR, Light KL, Marks LB. Is there an increased risk of local recurrence under the heart block in patients with left-sided breast cancer? Cancer J 2006; 12:309-17.
• Evans ES, Prosnitz RG, Xiaoli Yu X, Zhou SM, Hollis DR, M.S., Wong TZ, Light KL, Hardenbergh PH, Blazing M, Marks, LB.  “The Impact of Patient-Specific Factors, Irradiated Left-Ventricular Volume, and Treatment Set-up Accuracy on the Development of Myocardial Perfusion Defects Following Radiation Therapy for Left-Sided Breast Cancer.” Int J Radiat Oncol Biol Phys 2006; 66:1125-1134.
• Prosnitz RG, Patwardhan MB, Samsa GP, Mantyh CR, Fisher DA, McCrory DC, Cline KE, Gray RN, Morse MA.  Quality Measures for the Use of Adjuvant Chemotherapy and Radiation Therapy in Patients with Colorectal Cancer:  A Systematic Review.  Cancer 2006; 107:2352-2360.
• Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Cline KE, Gray RN.  “Cancer care quality measures: diagnosis and treatment of colorectal cancer.” Evid Rep Technol Assess (Full Rep). 2006; 138:1-116.
• Patwardhan MB, Fisher DA, Mantyh CR, McCrory DC, Morse MA, Prosnitz RG, Cline K, Samsa GP.  “Assessing the Quality of Colorectal Cancer Care: Do We Have Appropriate Quality Measures? (A systematic review of the literature.”  Journal of Evaluation in Clinical Practice 2007; 13:1831-1845.
• Prosnitz RG, Hubbs JL, Evans ES, Zhou SM, Yu X, Blazing MA, Holis DR, Tisch A, Wong TZ, Borges-Neto S, Hardenbergh PH, Marks LB.  “Prospective Assessment of Radiotherapy-associated Cardiac Toxicity in Breast Cancer Patients:  Analysis of Data 3 to 6 Years After Treatment.”  Cancer 2007; 110:1840-1850.
• Fatunase T, Wang Z, Yoo S, Hubbs JL , Prosnitz RG, Yin FF and Marks LB.  “Assessment of the residual error in soft tissue setup in patients undergoing partial breast irradiation: results of a prospective study using cone-beam computed tomography.  2008;70:1025-34

Editorials and Commentaries:

• Prosnitz, RG.  Commentary on Koukourakis, MI, et al.  “Hypofractionated and Accelerated Radiotherapy With Cytoprotection (HypoARC):  A Short, Safe, and Effective Postoperative Regiment for High-Risk Breast Cancer Patients.”  (Originally published in Int J Radiat Oncol Biol Phys 2002; 52:144-155.)  Included within Breast Diseases:  A Year Book Quarterly 2003;13:381-383.
• Prosnitz RG and Marks LB.  “Radiation-Induced Heart Disease—Vigilance is Still Required.”  J Clin Oncol 2005; 23:7391-7394.

Online Publications:

• Matchar DB, Kulasingam SL, Havrilesky L, Mann LO, Myers ER, McCrory DC, Patwardhan M and Prosnitz RG. Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular).Task Order No. 0. Prepared by the Duke University under Contract No. 290-02-0025. Rockville, MD: Agency for Health Care Policy and Research, March 2004). Available from: http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=92

• Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Cline KE, Gray RN. Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer. Evidence Report/Technology Assessment No. 138 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 0X-E00X-2. Rockville, MD: Agency for Healthcare Research and Quality. May, 2006.  Available from: http://www.ahrq.gov/downloads/pub/evidence/pdf/colocanqm/colocanqm.pdf#search=%22Cancer%20Care%20Quality%20Measures%20and%20Patwardhan%22.

• Marks, LB, Prosnitz, RG, Constine, LS, Adams, MJ. Cardiac effects of radiation therapy for malignancy. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, 2007.

Abstracts:

• Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM.  “Pretreatment hemoglobin levels are correlated with the effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.” Int J Radiat Oncol Biol Phys 2002; 54:S73.
• Marks LB, Prosnitz RG, Hardenbergh PH, Borges-Neto S, Wong T, Hollis D, Tisch A, Zhou SM, Blazing M.  “Functional consequences of radiation (RT)-induced perfusion changes in patients with left-sided breast cancer.”  Int J Radiat Oncol Biol Phys 2002; 54:S3-4.
• Prosnitz RG, Zhou SM, Hardenbergh PH, Marks LB.  “Long term radiation (RT)-induced cardiac perfusion defects following left sided tangential breast/chest wall irradiation.”  Breast Cancer Research and Treatment 2002; 76(Suppl. 1), #457.
• Yu X, Prosnitz, RG, Zhou SM, Hardenbergh PH, Tisch A, Blazing M, Borges-Neto S, Wong T, Hollis D, Marks LB.  “Symptomatic “cardiac” events following radiation therapy (RT) for left-sided breast cancer: Possible association with RT-induced changes in regional perfusion.”  Breast Cancer Research and Treatment 2002; 76(Suppl. 1), #458.
• Miller KL, Marks  LB, Bentley RC, Clough RW, Prosnitz RG, Leight GS.  “Does increased sectioning of ductal carcinoma in-situ (DCIS) pathologic specimens have clinical consequences?”  Breast Cancer Research and Treatment 2002; 76(Suppl. 1), #205.
• Quaranta P, Prosnitz RG, Light KL, Steffey B, Hardenbergh PH, Marks LB.  “Customized blocking of tangential radiation (RT) breast fields: excluding the heart vs. covering the breast. Striking a balance.”  Breast Cancer Research and Treatment 2002; 76(Suppl. 1), #460.
• Goldberg H, Prosnitz RG, Olson J, Marks LB.  “Definition of post-lumpectomy (L) tumor bed for radiotherapy (RT) boost field planning: computed tomography (CT) versus surgical clips.”  Breast Cancer Research and Treatment 2002; 76(Suppl. 1), #464.
• Prosnitz RG, Anscher MS, Huang H, Robert Clough R, Jirtle R, and, Marks LB.  “Does Pre-Treatment Plasma Transforming Growth Factor Beta1 (TGF-ß1) Level Predict Outcome In Breast Cancer Patients Following  Radiotherapy?”  Int J Radiat Oncol Biol Phys 2003; 57:S202-203.
• Marks LB, Yu X, Zhou S, Prosnitz RG, Hardenbergh P, Hollis D, Blazing M, Wong T, Coleman RE, Tisch A, Borges-Neto S. “The impact of irradiated left ventricular volume on the incidence  of radiation-induced cardiac perfusion changes.” Int J Radiat Oncol Biol Phys 2003; 57:S129
• Miften M, Prosnitz RG, Su M, Das S, Marks LB. “Incorporation of quality-of-life information into treatment plan ranking.” Int J Radiat Oncol Biol Phys; 57:S225.
• Quaranta BP, Clough RW, Kirkpatrick JP, Prosnitz RG, Rizzieri DA, Prosnitz LR. “Lymphocyte predominance Hodgkin’s Disease: high cure rate and acceptable complication rate with conventional treatment.” Int J Radiat Oncol Biol Phys 2004; 57:S284-S285.
• Allen AM, Prosnitz RG, Marks LB, Ten Haken RK, Yu X, Zhou S, Marsh R, Pierce LJ. “Body mass index (BMI) predicts the incidence of radiation pneumonitis (RP) in node-positive breast cancer.” Int J Radiat  Oncol Biol Phys 2003; 57:S130.
• Yu X, Zhou S, Kahn D, Hollis DR, Prosnitz RG, Hardenbergh PH, Blazing MA, Wong T, Borges-Neto S, Marks LB.  “Persistence of radiation (RT)-induced cardiac perfusion defects 3-5 years post RT.” Proc Am Soc Clin Oncol 2004; 23:33.
• Yu X, Zhou S, Prosnitz RG, Kahn D, Hardenbergh PH, Hollis DR, Tisch A, Blazing MA, Wong T, Borges-Neto S, Marks LB.  “Persistence of radiation (RT)-induced cardiac dysfunction 3-5 years post RT.”  Int J Radiat Oncol Biol Phys 2004; 60:S390-391.
• Prosnitz RG, Yu X, Zhou SM, D. Kahn D, Hollis DR, Hardenbergh PH, Borges-Neto S, Wong T, Blazing MA, Marks LB.  “Impact of patient-specific factors in the development of radiation (RT)-associated cardiac perfusion defects.” J Clin Oncol (Meeting Abstracts) 2004; 22: 45-a.
• Prosnitz RG, Yu X, Zhou S, Kahn D, Hollis D, Tisch A, Blazing MA, Wong T, Borges-Neto S, Hardenbergh P, Marks LB.  “The Importance of Daily Set-Up Accuracy in Preventing RT-Induced Cardiac Dysfunction in Patients Irradiated for Left-Sided Breast Cancer.” Int J Radiat Oncol Biol Phys 2004; 60:S296.
• Wong T, Zhou S, Prosnitz R, Hardenbergh P, Borges-Neto S, Coleman RE, Yu X, Blazing M, Marks LB.  “Challenges in Defining the Single Photon Emission Computed Tomography (SPECT) Defined Left-Ventricle: Implications in Studying Radiation (RT)-Induced Cardiac Dysfunction. Int J Radiat Oncol Biol Phys 2004; 60:S601-602.
• Raj KA, Hardenbergh P, Hollis D, Evans B, Prosnitz RG, Prosnitz L, Marks L.  “Local recurrence under the heart block in patients with left-sided breast cancer.” Int J Radiat Oncol Biol Phys 2004; 60:S403.
• Prosnitz RG, Evans ES, Zhou S, Hollis D, Hardenbergh P, Marks LB.  “Impact of Patient-Specific Factors on the Development of Myocardial Perfusion Defects (PD) Following Radiation Therapy (RT) for Left-Sided Breast Cancer.”  Proceedings of the 87th Annual Meeting of the American Radium Society 2005, p.20.
• Prosnitz RG, Evans ES, Zhou SM, Hollis D, Yu X,Kahn D,Blazing M, Hardenbergh P, Wong T, Marks LB.  “Objective vs. subjective assessment of single photon emission computed tomography (SPECT) cardiac perfusion scans to assess for Radiation Therapy (RT)-induced cardiac injury.” Int J Radiat  Oncol Biol Phys 2005; 63:S3-S4.
• Evans ES, Prosnitz RG, Yu S, Zhou SM, Hollis DR, Wong TZ, Light KL, Hardenbergh PH, Blazing MA, Marks LB.  “The Impact of Patient-Specific Factors on the Development of Radiation-Induced Cardiac Injury Following Treatment for Breast Cancer.”  Int J Radiat  Oncol Biol Phys 2005; 63:S189-S190.
• Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Samsa GP, Patwardhan MB.  “Quality measures for colorectal cancer diagnosis: a systematic review.”  Presented at Digestive Disease Week 2006.
• Evans ES, Yu XL, Prosnitz RG, Zhou SM, Wong TZ, Light K, Hardenbergh P, Blazing M, Marks LB, “Is there a Relationship between Body Mass Index, Treatment Set-up Errors, and the Development of Myocardial Perfusion Defects following Radiation Therapy for Left-Sided Breast Cancer?”.  Proceedings of the AAPM ,2006.
• Prosnitz RG, Patwardhan MB, Samsa GP, Mantyh CR, Fisher DA, McCrory DC, Cline KE, Gray RN, Morse MA.  Quality Measures for the Use of Adjuvant Chemotherapy and Radiation Therapy in Patients with Colorectal Cancer:  A Systematic Review.  Proceedings of the 88th Annual Meeting of the American Radium Society, 2006.
• Evans ES, Prosnitz RG, Yu S, Zhou S, Hollis DR, Wong TZ, Light KL, Hardenbergh PH, Blazing MA, Marks LB.  “The Impact of Patient-Specific Factors on RT-Induced Cardiac Perfusion Changes in Patients with Left-Sided Breast Cancer.”  Int J Radiat  Oncol Biol Phys 2006; 66:S92.
• Prosnitz RG, Evans ES, Zhou SM, Zhang J, Hollis D, Wong TZ, Borges-Neto S, Blazing MA, Hardenbergh PH, Marks LB.  “The Temporal Nature of RT-Induced Cardiac Perfusion Changes:  Analysis of the Dose-Response up to 5 Years Post-RT.”  Int J Radiat  Oncol Biol Phys 2006; 66:S105.
• Zhou S, Das S, Yan H, Zeng J, Zhang J. Mao J. Evans E, Tisch A, Prosnitz R, Marks L. “Identification of Predictors of RT-Induced Toxicity With the Random Forests Technique.” Int J Radiat  Oncol Biol Phys 2006; 66:S519.

Book Chapters:

• Shafman T, Yu X, Vujaskovic Z, Anscher MA, Miller K, Prosnitz RG, Marks LB.  “Radiation-Induced Lung and Heart Toxicity.”  In:  Medical Radiology:  Advances in Radiation Oncology in Lung Cancer. Jeremic B, Ed, Springer-Verlag, New York ,NY, 2004.
• Miften M, Gayou O , Parda DS, Prosnitz RG, and Marks LB.  “Radiation Bioinformatics: Using Quality of Life Information to Rationally Incorporate Normal Tissue Effects into Treatment Plan Evaluation and Scoring.”  In:  Medical Radiology:  Late Effects on Normal Tissues of Cancer Treatment.  P. Rubin, L.S. Constine, L.B. Marks, and P. Okunieff, Eds.  Springer-Verlag, New York, NY, 2007.
• Adams MJ, Prosnitz RG, Constine LS, Marks LB, Lipshultz SE.  “Screening for CVD in Survivors of Thoracic Radiation.”  In: Medical Radiology:  Late Effects of Cancer Treatment on Normal Tissues, pp 47-60.  Rubin P, Constine LS, Marks LB, Okunieff P, Eds.  Springer-Verlag, New York, NY, 2007.

Letters to Editors:

• Marks LB, Prosnitz RG, Evans ES. “In Reply to Dr. Gyenes.”  Int J Radiat  Oncol Biol Phys 2006.  64:1287-1288.
• Prosnitz RG, Haffty BG.  “What do recent studies on lumpectomy cavity volume change imply for breast clinical target volumes?”  Int J Radiat  Oncol Biol Phys 2008.  xx:xxxx-xxxx.

Presentations:                                                                                                                                     

• “Three-Dimensional Conformal Radiation Therapy Versus Prostate Brachytherapy.”  Coastal Oncology Prostate Cancer Symposium.  Wilmington, NC, October 20, 2001.
• “A Decision Analysis of Treatment Strategies for Clinically Localized Prostate Cancer in the PSA-Specific Era.”  Oral presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, Boston, MA, October 20, 2001.
• “Current Status of Radiotherapy for Early Stage Breast Cancer.” Ravanel Oncology Center’s 8th Annual Oncology Symposium.  Memorial Hospital.  Martinsville, VA, March 12, 2002.
• “Current Status of Radiotherapy for Early Stage Breast Cancer.”  Saint Mary’s Regional Cancer Center Breast Cancer Symposium,  Huntington, WV, September 27, 2002.
• “Radiotherapeutic Management of Prostate Cancer.”  Beaufort Memorial Hospital Fall Cancer Symposium, Jekyll Island, GA, October 19, 2002.
• “The Effect of Pretreatment Hemoglobin on Outcome Following RT and CCT for Advanced HNC.”  Oral Presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, New Orleans, LA, October 7, 2002.
• “Diffuse Large B-cell, Mantle Cell, and Burkitt’s Lymphoma.” National Comprehensive Cancer Network Practice Guidelines in Oncology:  Non-Hodgkins Lymphoma Guidelines Symposium, Duke Comprehensive Cancer Center, Durham, NC, November 22, 2002.
• “Update on Genitourinary Malignancies.”  Oncology Highlights 2003—Updates From ASCO, Greensboro, NC, June 20, 2003.
•  “Diffuse Large B-cell, Follicular, and Marginal Zone Lymphoma”.  Ravanel Oncology Center’s 9th Annual Oncology Symposium.  Memorial Hospital.  Martinsville, VA.  September 9, 2003.
•  “Current Status of Radiotherapy for Early Stage Breast Cancer.”  Duke Breast Oncology Femara Advanced Preceptorship, Durham, NC, July 30, 2003.
• “Does Pre-Treatment Plasma TGF-B1 Level Predict Outcome in Breast Cancer Patients Following Radiotherapy?  Oral presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, Salt Lake City, UT, October 21, 2003.
• “The Role of Radiotherapy in Non-Hodgkin’s Lymphoma.”  Duke Hematologic Malignancies Glaxo-Smith Kline Preceptorship,  Durham, NC,  November 7 and 21, 2003.
• “Accelerated Partial Breast Irradiation.”  Duke Oncology Network San Antonio Breast Cancer Conference Recap, Pinehurst, NC, February 21, 2004.
• “The Case for Consolidative Radiotherapy in Advanced Hodgkin’s Disease.”  Annual Meeting of the Carolina Regional Radiation Oncology Society (CARROS), Charlotte, NC,  March 6, 2004.
• “Current Status of Radiotherapy for Early Stage Breast Cancer.”  Duke Breast Oncology Novartis Preceptorship, Durham, NC, March 10, 2004.
• “The Case for Consolidative Radiotherapy in Advanced Stage Hodgkin’s Disease.”  Duke Debates—Controversies in the Management of Patients with Hematologic Malignancies, Asheville, NC,  April 2, 2004.
• “Radiotherapeutic Management of Early Stage Hodgkin’s Disease.”  Annual Meeting of the North Carolina Society of Radiologic Technologists, Durham, NC, April 17, 2004.
• “Radiotherapeutic Management of Early Stage Hodgkin’s Disease.”  Dept. of Radiation Oncology In-service, Durham, NC, May 21, 2004.
• “New Developments in Screening, Diagnosis and Local Therapy of Breast Cancer.”  Oncology Highlights 2004—Updates From ASCO, Greensboro, NC, June 18, 2004.
• “Impact of Patient-Specific Factors on the Development of Myocardial Perfusion Defects (PD) Following Radiation Therapy (RT) for Left-Sided Breast Cancer.”  Oral Presentation at the 87th Annual Meeting of the American Radium Society, Barcelona, Spain, April 30-May 4, 2005.
• “Treatment-Related Cardiac Toxicity in Patients Treated for Breast Cancer.  Era of Hope 2005 Department of Defense Breast Cancer Research Program Meeting, Pennsylvania Convention Center, Philadelphia, PA, June 8-11, 2005.
• “New Developments in the Radiotherapy for Early Stage Breast Cancer”.  First Annual Albemarle Hospital Symposium on the Treatment of Early Stage Breast Cancer Symposium, Albemarle Hospital, Elizabeth City, NC, September 22, 2005.
• “Objective vs. subjective assessment of single photon emission computed tomography (SPECT) cardiac perfusion scans to assess for Radiation Therapy (RT)-induced cardiac injury.”  Oral presentation (Plenary Session) at the American Society for Therapeutic Radiology and Oncology Annual Meeting, Denver, CO, October 18, 2005.
• “Quality Measures for the Use of Adjuvant Chemotherapy and Radiation Therapy in Patients with Colorectal Cancer:  A Systematic Review.”  Poster Presentation at 88th Annual Meeting of the American Radium Society, Maui, HI, May 6-10, 2006.
• “New Developments in Screening, Diagnosis and Local Therapy of Breast Cancer.”  Oncology Highlights 2006—Updates From ASCO, Greensboro, NC, June 23, 2006.
• “The Temporal Nature of RT-Induced Cardiac Perfusion Changes:  Analysis of the Dose-Response up to 5 Years Post-RT.”  Oral Presentation at the American Society for Therapeutic Radiology and Oncology Annual Meeting, Philadelphia, PA, November 5-9, 2006.
• “Radiotherapeutic Management of Early Stage Hodgkin’s Disease”.   New England Society of Radiotherapy Technologists Annual Meeting, Newport, RI, April 4-5, 2008.

Cooperative Groups Activities:
	1.   Radiation Therapy Oncology Group Member, 2005-present
		Site Principal-Investigator, RTOG 9804, “Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In-Situ (DCIS) of the Female Breast.”  DUMC IRB# 7012-05-3.  2001-2005.
		Site Principal Investigator, RTOG 0413 (NSABP Protocol B-39), “A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer.”  DUMC IRB # 7316-05-6.  2006-2007.

Journal Activities:

• International Journal of Radiation Oncology, Biology, and Physics, Reviewer, 2005-present
• Nature Clinical Practice Oncology, Reviewer, 2005-present
• Cancer Journal Scientific American, Reviewer, 2006-present

Administrative Responsibilities:

• Medical Liaison, Continuing Medical Education Program, Duke University Medical Center, Dept. of Radiation Oncology, 2001-2007.

Committee Memberships:

• Member, Resident Education Committee, Duke University Medical Center, Dept. of Radiation Oncology, 2001-2007.
• Member, Duke Cancer Center Quality Improvement Committee, 2005-2007.
• Member, Duke University Medical Center Quality Improvement Committee, 2005-2007.
• Member, Dept of Radiation Oncology Website Redesign Committee, 2005.

Volunteer Activities
	Board Member, Duke Cancer Patient Support Program, 2001-2005
Hobbies and Interests:
	Soccer, triathlon, weight training, and downhill skiing

Revised 2/25/09

 

 

» TOP

© University of Pennsylvania | School of Medicine | University of Pennsylvania Health System